JZJinsong Zhang

Jinsong Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jinsong Zhang has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Airway administered artificial mitochondria-enriched nanovesicles for efficient and selective mitochondria transfer to intervene in pulmonary fibrosis

    by Jinsong Zhang, Siying Fu, Jiawen Wang, Honghui Wu, Zhuoting Li, Ruyi Lin, Hao Sun, Seungho Choe, Yuhuan Kong, Donghang Xu, et al.

    Mitochondrial transplantation is a promising therapeutic approach involving the transfer of exogenous mitochondria into diseased cells to restore impaired mitochondrial homeostasis. However, its clinical translation is severely limited by the lack of efficient methods for precise and potent mitochondria transfer. Inspired by natural mitochondria-containing vesicles, we develop mesenchymal stem cell-derived biomimetic nanovesicles with high mitochondrial loading capacity and augmented extracellular mitochondrial stability. These nanovesicles exhibit an ability to efficiently and selectively deliver mitochondrial cargo to injured cells, which is potentially ascribed to the specific interaction between very late antigen-5 on the nanovesicle surface and pathologically upregulated fibronectin on injured cells. In a mouse pulmonary fibrosis model, these nanovesicles successfully deliver healthy mitochondria to injured lung epithelial cells through airway administration, resulting in a significant reduction in fibrotic progression. This study introduces a design of mitochondria-enriched biomimetic nanovesicles for effective and targeted mitochondria transfer, offering a nanotechnology-based strategy to advance mitochondrial transplantation therapy.

  • Open Access

    Unveiling the bioactive landscape of drug inactive ingredients (DIGs) using deep transfer learning

    by Minjie Mou, Jinsong Zhang, Xingang Liu, Hao Yang, Tingting Fu, Hengbin Zhang, Yimiao Zhu, Tianle Niu, Xuedong Li, Yichao Ge, et al.


  • Open Access

    Periodic asymmetric field enhances electrofusion of nanoscale lipid systems

    by Honghui Wu, Wen-Che Liu, Xuanyu Wu, Zhuoting Li, Jialu Zhang, Jiawen Wang, Qing Zhu, Jinsong Zhang, Kairu Dong, Ruyi Lin, et al.

    Electrofusion is a widely used technique for inducing membrane merging in biological systems, with applications ranging from hybrid lipid architectures to therapeutic delivery. However, the direct application of conventional electrofusion to advanced nanoscale drug carriers, such as cell membrane hybrid LNPs (cLNPs), faces challenges due to diminished dielectric response and uncontrolled particle dynamics. To address these limitations, we report a periodic asymmetric field (PAF) strategy that combines microfluidic flow with periodic electric fields to enhance nanoscale electrofusion. We systemically investigate the underlying mechanisms using computational fluid dynamics simulations, and subsequently fabricate and optimize a PAF-guided microfluidic electrofusion device (PAF-MED) for the controlled synthesis of cLNPs. These PAF-MED-synthesized cLNPs demonstrate improved fusion efficiency, augmented targeting capability, and superior therapeutic efficacy in bleomycin-induced pulmonary fibrosis murine models. This approach represents a unique advancement in the nanoscale manipulation of drug carriers towards better bio-functionality and reproducibility beyond conventional capability of electrofusion.


  • A large‐scale production of mesenchymal stem cells and their exosomes for an efficient treatment against lung inflammation

    by Jinsong Zhang, Ruyi Lin, Yingyu Li, Jiawen Wang, Huiqing Ding, Panfeng Fang, Yingzhi Huang, Jing Shi, Jianqing Gao, Tianyuan Zhang

    Mesenchymal stem cells (MSCs) and their produced exosomes have demonstrated inherent capabilities of inflammation‐guided targeting and inflammatory modulation, inspiring their potential applications as biologic agents for inflammatory treatments. However, the clinical applications of stem cell therapies are currently restricted by several challenges, and one of them is the mass production of stem cells to satisfy the therapeutic demands in the clinical bench. Herein, a production of human amnion‐derived MSCs (hMSCs) at a scale of over 1 × 109 cells per batch was reported using a three‐dimensional (3D) culture technology based on microcarriers coupled with a spinner bioreactor system. The present study revealed that this large‐scale production technology improved the inflammation‐guided migration and the inflammatory suppression of hMSCs, without altering their major properties as stem cells. Moreover, these large‐scale produced hMSCs showed an efficient treatment against the lipopolysaccharide (LPS)‐induced lung inflammation in mice models. Notably, exosomes collected from these large‐scale produced hMSCs were observed to inherit the efficient inflammatory suppression capability of hMSCs. The present study showed that 3D culture technology using microcarriers coupled with a spinner bioreactor system can be a promising strategy for the large‐scale expansion of hMSCs with improved anti‐inflammation capability, as well as their secreted exosomes.